Human papillomavirus and vaccine knowledge, willingness, and uptake among university students: a systematic review and meta-analysis Authors: Wenjing Li, Yinji Jin, Xiang Li, Meixiang Jin Published: 2025 ABSTRACT BackgroundPersistent infection with high-risk human papillomavirus (HPV) types is a well-established risk factor for various malignancies, and timely vaccination of university students is a cost-effective strategy to reduce infection rates and the burden of HPV-associated consequences. Although many studies have examined HPV knowledge, vaccine acceptance, and uptake in university students, findings remain heterogeneous, and comprehensive quantitative synthesis is limited. This systematic review and meta-analysis aims to assess global estimates of university students’ knowledge of HPV and its vaccine, willingness to receive the vaccine, and actual vaccination behaviors.MethodsThe study was reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 Checklist. A systematic search was conducted in PubMed, Web of Science, China Biology Medicine disc, China National Knowledge Infrastructure and Wan Fang Database for studies published from January 2006 through August 2024. Studies with quality assessment scores > 5 and published in Chinese or English were included for data extraction. Pooled prevalence estimates and 95% confidence intervals (CI) were calculated using the Freeman-Tukey double arcsine transformation. The heterogeneity statistic I-squared and corresponding p value were also reported.ResultsA total of 56 studies covering 184,351 university students from four continents (Asia, Africa, Europe and North America) were included. Among students, 68.3% (95% CI 56.4%-79.0%) and 53.5% (95% CI 53.0%-54.1%) were aware of HPV and HPV vaccine, respectively, with significant gaps in knowledge about HPV symptoms, cervical cancer screening methods, and optimal vaccination timing. Pooled HPV vaccination willingness was 52.9% (95% CI 44.2%-61.6%), with higher willingness observed among females and medical students. Only 10.4% (95% CI 6.1%-15.8%) had received at least 1 dose of vaccination and 12.4% (95% CI 3.0%-26.9%) had completed the full three-dose schedule. Vaccination coverage among females was 8.6% (95% CI 3.7%–15.1%), and among medical students, 7.7% (95% CI 1.3%-18.4%).ConclusionsThis meta-analysis found that university students exhibit limited awareness of HPV and its vaccine, with about half willing to be vaccinated. Actual vaccination rates remain low and vary widely by gender, major, time of year, and geographic regions. These findings highlight the need for targeted intervention strategies, such as precision education and cross-sector collaboration, to effectively increase HPV vaccination coverage in this population.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-025-25626-4. Introduction The World Health Organization (WHO) recognizes hepatitis B and human papillomavirus (HPV) as two common sexually transmitted infections (STIs) that can be effectively prevented through safe and reliable vaccination programs [1]. University students are particularly vulnerable to STIs due to more open sexual attitudes, a weaker sense of self-protection, earlier sexual debut, and increased engagement in risky sexual activities facilitated by the popularity of social media and digital platforms [2–4]. Therefore, timely HPV vaccination is therefore strongly recommended for this population to reduce the incidence of HPV-related diseases. HPV is a highly prevalent virus that causes proliferative lesions on the skin and mucous membranes of the body, and almost all sexually active individuals will be infected with HPV at some point in their lives [5, 6]. Although HPV infections are usually asymptomatic, persistent infection with high-risk HPV types can lead to the development of cancer. It is important to note that HPV infection does not discriminate between sexes, and it is responsible for over 95% of cervical cancers and 60% of penile cancers [7]. Prior evidence demonstrates the effectiveness of HPV vaccination in reducing HPV infection and preventing HPV-related cancers [8]. A meta-analysis reported a 66% reduction in the prevalence of HPV types 16 and 18 in females aged 20–24 years, 5–8 years after vaccination [9]. Based on health economic evaluations [10, 11], HPV vaccination was more cost-effective in the adolescents (females aged 12–26, males aged 12–21) than in mid-adulthood (27–45 years old), with an estimated cost of $9,200 per quality-adjusted life-year (QALY) gained. In contrast, cost-effectiveness drops substantially (>$650,000/QALY) when vaccination is extended to adults aged 45 years. The study suggests that combined strategies, such as vaccination plus cervical cancer screening is cost-effective for females, especially in areas with high vaccination coverage. Nonetheless, the incremental cost-effectiveness ratios (ICERs) for related screening strategies often exceed the willingness to pay (WTP) threshold when vaccination rates reaches 85% and protection duration lasts at least 20 years [12, 13]. Vaccination is also likely cost-effective for men, particularly homosexual men [14]. Currently, 143 countries have included the HPV vaccine and related services in their national immunization schedules [15], but coverage remains insufficient. Vaccination rates vary significantly across countries of different income levels [16], with particularly wide disparities among university students. It is important to note that university student vaccination rates are influenced by the broader vaccination landscape of their respective countries. In high-income countries such as France and the US, where national immunisation systems are well-established and overall HPV vaccination coverage is relatively high, university students also benefit from accessible vaccination services. In 2020, the HPV vaccine was received by 41.7% of university students in France [17], and the vaccination rate among U.S. university students reached 53.3% in 2021[18]. By contrast, systemic constraints in low-income countries limit overall population coverage and hinder vaccination opportunities for university students. For example, less than 5% of university students in Ethiopia were vaccinated in 2021[19], and only 19.5% in the South African capital, Pretoria, had received the vaccine in 2023[20]. Vaccination behavior is influenced by individuals’ willingness to vaccinate [21], which also varies by country [22]. For instance, willingness to vaccinate among university students in Turkey is 15.7%, while in China, it can reach 82.9%[23, 24]. Factors influencing vaccine willingness include socioeconomic status, cultural background, and the political environment [25]. Mussetto et al.[26] found that individual cognition, the perceived risk of infection and recommendations from healthcare professionals all played a significant role in shaping attitudes towards HPV vaccination. HPV vaccination rates among university students vary significantly across the globe, and the underlying mechanisms of these disparities require analysis at multiple levels. Current research tends to focus on specific regions or schools, primarily examining individual-level factors such as knowledge, willingness and behaviours. In fact, in areas with high vaccine accessibility, individual factors such as knowledge and willingness may indeed be key determinants of vaccination behaviour. Conversely, in areas with limited vaccine accessibility, increasing the supply of vaccines is the primary prerequisite for promoting vaccination. These disparities highlight the need for comprehensive global research. This study uses systematic review and meta-analysis methods to evaluate the current level of knowledge about HPV and its vaccines, willingness to be vaccinated, and vaccination rates among university students worldwide. The study also explores the key factors influencing vaccination behaviour, providing scientific evidence to inform the development of targeted intervention strategies. Methods Study design This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA 2020) guidlines [27]. The review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD420251149589). The review process was guided by the Joanna Briggs Institute (JBI) Manual for Evidence Synthesis [28]. This analysis was reported using the PRISMA 2020 statement checklist (See S1 PRISMA 2020 Checklist). Search strategy and selection criteria A systematic literature search was performed in two English-language databases (PubMed and Web of Science) and three Chinese-language databases (China Biology Medicine disc, China National Knowledge Infrastructure, and Wan Fang Database) with search terms including: ‘HPV’, ‘cervical cancer’, ‘Papillomavirus’, ‘vaccine’, ‘immunization’, ‘awareness’, ‘acceptability’, and ‘attitude’. Specific search strategies for each database are detailed in the Appendix. The search period was from 1 January 2006 to 5 August 2024. After consolidating all search records and eliminating duplicates, an initial screening was performed based on titles and abstracts, followed by full-text review of potentially eligible studies. Studies were included if they met the following criteria: (1) the cross-sectional study design; (2) target population consisted of university students worldwide; (3) outcome indicators included at least one of the keywords “HPV vaccine-related knowledge”, “willingness to vaccinate”, or"vaccination rate”; (4) quality score ≥ 5; (5) article published in Chinese or English. Studies were excluded if: (1) the design was an intervention study; (2) basic and essential data were missing or could not be recalculated; (3) publication types were conference abstracts, case reports, letters, comments, editorials, or review articles, etc.; (4) duplicated literature; (5) the quality score was < 5. Literature screening was conducted independently by two researchers (WL and YJ). Any literature with disagreement was discussed with the third researcher (MJ) to decide on inclusion or exclusion. Duplicate checks were performed using EndNote software, while the screening process was completed the Rayyan online tool. Data abstraction and quality assessment For each included study, we created a table of basic characteristics and extracted the following data: title, first author, publication date, study location, sample size, and population characteristics, such as education, specialty, ethnicity, age, and sex. In addition, we extracted the number of individuals used to assess HPV vaccine-related perceptions, vaccine uptake and vaccination. Study quality of the included literature was assessed using the Agency for Healthcare Quality and Research (AHRQ) criteria for cross-sectional studies [29, 30], which consists of 11 items rated as ‘yes’, ‘no’ or ‘unclear’. Studies scoring >5 were considered high quality. Literature data extraction and quality assessment were performed independently by WL and YJ, and disagreements were resolved in consultation with the third researcher, MJ, when present. Statistical analysis Statistical analyses were performed using R software (version 4.3.3), specifically the “meta” and “metafor” packages. The Freeman-Tukey double arcsine transformation was applied to stabilise the variance in data based on event counts and sample sizes [31]. Study weights were determined using the inverse variance method, whereby the weight of each study was inversely proportional to the variance of its effect size. Studies with lower variance were given greater weight to minimise the impact of random error on the pooled results. The weighted inverse variance method was then used to calculate the pooled prevalence estimate and its corresponding 95% confidence interval (CI). Heterogeneity across included studies was analysed using I2. When I2 < 50% and P > 0.05, heterogeneity was low, and a fixed-effects model was used. When I2 ≥ 50% and P < 0.05, heterogeneity was deemed substantial, and a random-effects model was applied. Sensitivity analyses were performed by culling of individual original studies one at a time to evaluate the robustness of results. Subgroup analyses were conducted by gender, academic major, survey year, and geographic region in order to gain a better understanding of the current status of HPV vaccination among university students. Egger’s test and funnel plot were used to assess publication bias [32], with a significance threshold of α = 0.05. Forest plots were constructed to visually summarize and compare effect sizes across studies. Results Search results and quality assessment Figure 1 presents the screening process according to the PRISMA guidelines. An initial search using the search formula yielded 14,750 documents. After removing duplicates and screening titles and abstracts, 337 articles remained. Following full-text review, 5 articles were excluded for reasons including language mismatch (n = 1), study population mismatch (n = 1), and data irrelevance to the research question (n = 3). Fig. 1Flow diagram of literature selection Flow diagram of literature selection After a rigorous quality assessment of all included cross-sectional studies, only 56 studies met high quality standards (scoring > 5) (See Appendix 2 for detailed scoring). The remaining 276 studies were further excluded due to lower quality, with 125 of these providing valuable evidence and classification as moderate quality and listed separately in the appendix (See Appendix References of moderate quality). This review ultimately included 56 studies, all of which were cross-sectional surveys. Characteristics of included studies There were 56 high-quality studies in total, which were conducted across 4 major continents (See Appendix 1 Characteristics of 56 included studies): 44 in Asia, 4 in Africa, 4 in Europe and 4 in North America. Those 25 studies included samples composed of more than 80% undergraduates, 39 involved medical students, 15 included racial/ethnic minority populations, and 44 had more than half females. The average age of the study population was approximately 20 years old. The sample sizes ranged from 102 to 9,988, totaling 184,351 participants. Knowledge about HPV and vaccination Table 1 summarizes findings on HPV and vaccine-related knowledge among university students. Overall, 68.3% (95% CI 56.4%–79.0%) were aware of HPV, though Potential publication bias was detected (Egger’s test P = 0.0231). In contrast, only 53.5% (95% CI 53.0%–54.1%) were aware of the HPV vaccine, with no publication bias identified (P = 0.2865). The highest level of awareness was observed for the knowledge that having multiple sexual partners is a high-risk factor for HPV infection (70.6%, 95% CI 55.7%–83.5%), while the lowest was for the fact that HPV infection may show no symptoms (37.3%, 95% CI 18.7%–58.0%), with no publication bias (P = 0.8523). Nearly half of university students (49.8%, 95% CI 42.1%–57.5%) were aware that early sexual activity increases the risk of HPV infection, and 56.8% (95% CI 49.6%–64.0%) knew that HPV could be transmitted through sexual contact. Publication bias was not detected for these items (P = 0.1193). The results also indicated that the majority of university students lacked knowledge about cervical cancer screening methods and the optimal timeing to receive the HPV vaccine. Only 48.6% (95% CI 42.7%–54.6%) and 52.2% (95% CI 42.3%–62.1%) answered these questions correctly, respectively, with no publication bias (P = 0.2779). 60.7% (95% CI 39.9%–79.7%) of university students were aware that HPV includes both high-risk and low-risk types, and 65.7% (95% CI 45.3%–83.5%) had knowledge of the transmission routes of HPV. In addition, knowledge of female cancers mainly caused by HPV infection also remained insufficient, with only 65.0% (95% CI 59.1%–70.7%) of students answering correctly, and no bias identified (P = 0.3939) (See Appendix Figure S1-S11). Table 1Knowledge of HPV and HPV vaccination among university studentsHPV and HPV vaccination related knowledgeNumber of studiesPooled effect estimate (95%CI)Heterogeneity testEffect modelEgger’s test (P)I2 (%) P Heard of HPV230.683 (0.564–0.790)99.6< 0.001Random effects model0.0231Heard of the HPV vaccine250.506 (0.404–0.607)99.6< 0.001Random effects model0.2865The optimal time to get HPV vaccinated140.522 (0.423–0.621)99.0< 0.001Random effects model0.2779HPV infection may show no symptoms110.373 (0.187–0.580)99.5< 0.001Random effects model0.8523HPV can be transmitted through sexual contact210.568 (0.496–0.640)98.3< 0.001Random effects model0.1193HPV virus can be divided into high-risk type and low-risk type30.607 (0.399–0.797)98.7< 0.001Random effects model-Multiple sexual partners are high risk factors50.706 (0.557–0.835)98.4< 0.001Random effects model-The age of frst sexual life is too early and easy to be infected with HPV60.498 (0.421–0.575)94.5< 0.001Random effects model-The route of transmission of HPV30.657 (0.453–0.835)98.3< 0.001Random effects model-Female cancer mainly caused by HPV infection280.650 (0.591–0.707)98.9< 0.001Random effects model0.3939Know the method of screening cervical cancer30.486 (0.427–0.546)73.00.025Random effects model- Table 1Knowledge of HPV and HPV vaccination among university studentsHPV and HPV vaccination related knowledgeNumber of studiesPooled effect estimate (95%CI)Heterogeneity testEffect modelEgger’s test (P)I2 (%) P Heard of HPV230.683 (0.564–0.790)99.6< 0.001Random effects model0.0231Heard of the HPV vaccine250.506 (0.404–0.607)99.6< 0.001Random effects model0.2865The optimal time to get HPV vaccinated140.522 (0.423–0.621)99.0< 0.001Random effects model0.2779HPV infection may show no symptoms110.373 (0.187–0.580)99.5< 0.001Random effects model0.8523HPV can be transmitted through sexual contact210.568 (0.496–0.640)98.3< 0.001Random effects model0.1193HPV virus can be divided into high-risk type and low-risk type30.607 (0.399–0.797)98.7< 0.001Random effects model-Multiple sexual partners are high risk factors50.706 (0.557–0.835)98.4< 0.001Random effects model-The age of frst sexual life is too early and easy to be infected with HPV60.498 (0.421–0.575)94.5< 0.001Random effects model-The route of transmission of HPV30.657 (0.453–0.835)98.3< 0.001Random effects model-Female cancer mainly caused by HPV infection280.650 (0.591–0.707)98.9< 0.001Random effects model0.3939Know the method of screening cervical cancer30.486 (0.427–0.546)73.00.025Random effects model- Knowledge of HPV and HPV vaccination among university students Vaccination willingness rate Of the 56 high-quality studies in the literature, university students’ willingness to receive HPV vaccination was evaluated across different geographic regions in 35 of them. The pooled willingness rate for HPV vaccination among university students was 52.9% (95% CI 44.2%–61.6%) (Fig. 2). Analysis of publication bias indicated a potential publication bias (P = 0.0418). Fig. 2Forest plot of HPV vaccination willingness rate among university students Forest plot of HPV vaccination willingness rate among university students In the gender subgroup analysis, willingness to be vaccinated against HPV was estimated to be 59.4% (95% CI 41.8%–75.9%) among females and 45.4% (95% CI 17.9%–74.5%) among males, with significant heterogeneity observed between groups (I2 = 99.7%, P < 0.001). The results of the subgroup analysis on both willingness to vaccinate and vaccination rates are shown in Table 2. In subgroup analyses by academic specialty, the HPV vaccination uptake rate of the medical student group was 60.5% (95%CI 28.9%–87.9%) compared to 27.9% (95% CI 19.8%–36.7%) among non-medical students, with significant heterogeneity between groups (I2 = 99.6%, P < 0.001). Overall vaccination intentions of medical students were higher than those of non-medical students (See Appendix Figure S12, S13). Table 2The outcomes of the meta-analysis of dichotomous variableSubgroupNumber of studiesPooled effect estimate (95%CI)Heterogeneity testEffect modelTest for subgroup differences (P)I2 (%) P Vaccination Willingness Gender Female130.594 (0.418–0.759)99.7< 0.001Random effects model0.4304 Male40.454 (0.179–0.745)99.7< 0.001Random effects model Major Medicine70.605 (0.289–0.879)99.6< 0.001Random effects model0.0506 Non-medicine20.279 (0.198–0.367)93.4< 0.001Random effects model Time 2010–201530.379 (0.052–0.791)99.6< 0.001Random effects model0.7627 2016–2020120.538 (0.390–0.683)99.7< 0.001Random effects model 2021–2024200.546 (0.427–0.663)99.6< 0.001Random effects model Region Asia280.563 (0.473–0.651)99.5< 0.001Random effects model0.4517 Africa40.329 (0.045–0.716)99.6< 0.001Random effects model Europe20.433 (0.085–0.826)99.8< 0.001Random effects model North America-----Vaccination Gender Female110.086 (0.037–0.151)98.9< 0.001Random effects model- Male----- Major Medicine70.077 (0.013–0.184)99.1< 0.001Random effects model0.5073 Non-medicine20.259 (0.000–0.908.000.908)99.9< 0.001Random effects model Time 2010–201560.066 (0.019–0.138)98.0< 0.001Random effects model0.5114 2016–202080.132 (0.044–0.257)99.6< 0.001Random effects model 2021–2024170.106 (0.046–0.188)99.4< 0.001Random effects model Region Asia200.059 (0.039–0.082)96.8< 0.001Random effects model< 0.0001 Africa30.036 (0.015–0.067)81.50.005Random effects model Europe40.314 (0.172–0.476)99.2< 0.001Random effects model North America40.293 (0.137–0.479)99.0< 0.001Random effects modelAs there were fewer than 10 studies in each group of subgroup analyses, we only plotted funnel plots Table 2The outcomes of the meta-analysis of dichotomous variableSubgroupNumber of studiesPooled effect estimate (95%CI)Heterogeneity testEffect modelTest for subgroup differences (P)I2 (%) P Vaccination Willingness Gender Female130.594 (0.418–0.759)99.7< 0.001Random effects model0.4304 Male40.454 (0.179–0.745)99.7< 0.001Random effects model Major Medicine70.605 (0.289–0.879)99.6< 0.001Random effects model0.0506 Non-medicine20.279 (0.198–0.367)93.4< 0.001Random effects model Time 2010–201530.379 (0.052–0.791)99.6< 0.001Random effects model0.7627 2016–2020120.538 (0.390–0.683)99.7< 0.001Random effects model 2021–2024200.546 (0.427–0.663)99.6< 0.001Random effects model Region Asia280.563 (0.473–0.651)99.5< 0.001Random effects model0.4517 Africa40.329 (0.045–0.716)99.6< 0.001Random effects model Europe20.433 (0.085–0.826)99.8< 0.001Random effects model North America-----Vaccination Gender Female110.086 (0.037–0.151)98.9< 0.001Random effects model- Male----- Major Medicine70.077 (0.013–0.184)99.1< 0.001Random effects model0.5073 Non-medicine20.259 (0.000–0.908.000.908)99.9< 0.001Random effects model Time 2010–201560.066 (0.019–0.138)98.0< 0.001Random effects model0.5114 2016–202080.132 (0.044–0.257)99.6< 0.001Random effects model 2021–2024170.106 (0.046–0.188)99.4< 0.001Random effects model Region Asia200.059 (0.039–0.082)96.8< 0.001Random effects model< 0.0001 Africa30.036 (0.015–0.067)81.50.005Random effects model Europe40.314 (0.172–0.476)99.2< 0.001Random effects model North America40.293 (0.137–0.479)99.0< 0.001Random effects modelAs there were fewer than 10 studies in each group of subgroup analyses, we only plotted funnel plots The outcomes of the meta-analysis of dichotomous variable As there were fewer than 10 studies in each group of subgroup analyses, we only plotted funnel plots In terms of time distribution, the HPV vaccination willingness rate of university students was 37.9% (95% CI 5.2%–79.1%) during 2010–2015, increased to 53.8% (95%CI 39.0%–68.3%) in 2016–2020, and reached 54.6% (95% CI 42.7%–66.3%) in 2021–2024. However, significant heterogeneity persisted across time periods (I2 = 99.6%, P < 0.001). Acceptance of the HPV vaccine among university students continued to increase over time (See Appendix Figure S14). From the regional distribution, a total of 28 studies were conducted in Asia and reported a willingness to vaccinate of 56.3% (95% CI 47.3%–65.1%), while 4 studies from Africa reported a rate of 32.9% (95% CI 4.5%–71.6%). Only 2 studies were conducted in Europe with a reported willingness rate of 43.3% (95% CI 8.5%–82.6%). Heterogeneity remained significant (I2 = 99.6%, P < 0.001). The forest plot was shown in Appendix Figure S15. Vaccination rate Thirty-one studies reported vaccination rates among university students who had received at least one dose of the HPV vaccine, while five studies reported rates among those who had completed the full three-dose series. The pooled analysis revealed that 10.4% (95% CI 6.1–15.8%) of university students had received at least one dose of the HPV vaccine (Fig. 3). Publication bias analysis revealed no evidence of publication bias (P = 0.1417). Additionally, 12.4% (95% CI 3.0%−26.9%) of students had received all 3 doses of the HPV vaccine (Fig. 4). Fig. 3Forest plot of HPV vaccination coverage among university students Forest plot of HPV vaccination coverage among university students Fig. 4Forest plot of HPV vaccine completion of full vaccination coverage among university students Forest plot of HPV vaccine completion of full vaccination coverage among university students When the analysis was restricted to female students, the vaccination rate was 8.6% (95% CI 3.7%−15.1%), with significant heterogeneity between groups (I2 = 98.9%, P < 0.001). Only female-specific vaccination rates are presented here, as there were no male-only data from the included high-quality studies. If limited to medical students, the vaccination rate was 7.7% (95% CI 1.3%−18.4%), while the rate among non-medical students was 25.9% (95% CI 0%−90.8%), with significant heterogeneity between groups (I2 = 99.5%, P < 0.001). Forest plots could be found in Figures S16 and S17 of the Appendix. Vaccination rates also varied over time. the reported vaccination rate was6.6% (95%CI 1.9%−13.8%) in 2010–2015, reached 13.2% (95% CI 4.4%−25.7%) in 2016–2020, and was 10.6% (95% CI 4.6%−18.8%) in 2021–2024 (See Appendix Figure S18), with significant heterogeneity between the groups (I2 = 99.5%, P < 0.001). Regional differences in HPV vaccination rates were also evident. In Europe, 31.4%(95% CI 17.2%−47.6%) of university students were vaccinated against HPV, followed by 29.3% (95% CI 13.7%−47.9%) in North America, both higher than the 5.9% (95% CI 3.9%−8.2%) reported in Asia and the 3.6% (95% CI 1.5%−6.7%) reported in Africa. Heterogeneity was significant (I2 = 99.5%, P < 0.001). Figure S19 in the Appendix showed the forest plot. Discussion This study conducted a pooled analysis of HPV and its vaccine knowledge, willingness to vaccinate, and vaccination rates among university students worldwide. Raising public awareness has always been the focus of public health services, which aims to ensure that individuals understand the benefits of vaccination [33]. We found that university students’ overall knowledge of HPV and the HPV vaccine was limited, with 68.3% and 50.6% awareness, respectively. This suggests that students are more familiar with HPV itself than with the vaccine, highlighting the need to further strengthen education and promotion efforts focused specifically on the HPV vaccine. Previous studies have suggested [34–36] that this difference may be stem from the different study times, settings, and population characteristics. For example, The study on Italian university students reported high awareness rates, with both their knowledge of HPV and its vaccine reaching more than 80%, identifying the Internet, healthcare professionals, teachers, and family members as the main sources of information. teachers and healthcare professionals, in particular, were found to be highly trusted by the university students [37, 38]. Based on these findings, we recommend that universities actively carry out HPV education programs and invite experts in the fields of medicine and public health to deliver professional lectures [39, 40]. In the design of the curriculum, emphasis should be placed on discussion sessions to build an interactive platform for students to participate in depth, so as to transform passive acceptance of knowledge into active thinking, and to effectively enhance the learning effect [41]. It is worth noting that, in our study, the highest level of knowledge among university students pertained to the role of multiple sexual partners as a high risk factor, while the lowest related to the fact that HPV infection can be asymptomatic. this indicates that university students’ actual knowledge of HPV infection is biased and not comprehensive enough, with limited awareness of the risk factors, consequences and transmission routes. In addition, university students demonstrated limited knowledge of the optimal timing of cervical cancer screening and vaccination, which are critical information that could otherwise support informed vaccination decisions. To address these gaps, schools and public health service centres should regularly assess students’ awareness and ensure that comprehensive, accurate HPV-related information reaches this population to enhance their health awareness and protective behaviors [42–44]. The Meta-analysis found that the pooled rate of willingness to vaccinate against HPV was 52.9%, a figure similar to the 54% reported in an earlier meta-analysis of university students [26]. This indicates that despite the effectiveness of HPV vaccine in preventing HPV infection and related diseases has been scientifically proven [9], nearly half of the university students are still hesitant or refuse to take HPV vaccine. At the same time, we observed an increasing trend of HPV vaccination willingness from 2010 onwards. This may be due, in part, to increasing openness about sexuality among university students [45–47], and the prevalence of high-risk sexual behaviors, including multiple sexual partners and inconsistent condom use [48, 49]. many studies have well documented and confirmed such high-risk sexual behaviours in the university student population [50–52]. Moreover, the widespread dissemination of health information through the Internet and social media [53, 54] may also encourage university students to gradually accept the vaccine and then proactively seek vaccination protection [55]. There are differences in HPV vaccination willingness in different regions, which may reflect variations in the geographic areas covered by the studies, population characteristics, and cultural backgrounds. HPV vaccination was first approved in the United States in 2006 and has since been gradually approved in various countries [56]. However, in areas with lower levels of economic development, limited medical infrastructure and public health resources have restricted access to vaccines [57, 58]. Under these circumstances, university students may view HPV vaccination as a non-essential expense, which reduces willingness to vaccinate. In addition, we found that the HPV vaccination rate was low, with only 11% of university students having received the HPV vaccine in 2021–2024, a rate much lower than the vaccination willingness rate, a phenomenon commonly seen in previous cross-sectional studies in different regions, suggesting that while many students express intent, few follow through with vaccination [19, 59, 60]. In subgroup analyses, females (59.4%) were more likely to receive the HPV vaccine than males (45.4%), likely due to the vaccine’s established role in preventing cervical cancer [61]. This has prompted females to actively seek vaccination, while males may assume that they are not at risk and thus neglect vaccination [62, 63]. Secondly, females tend to have higher health awareness [64], and are more concerned about their health issues, especially reproductive health-related diseases, and are more willing to include HPV vaccination in their health planning. Due to a lack of male-specific data the included studies, only female vaccination rate of 8.6% were reported, which is similar to the overall vaccination rate. at the same time, we found that a relatively high percentage of females received all 3 doses of vaccine, indicating greater vaccine awareness and proactive health behavior among females [65]. Based on this, schools can build on their strong focus on health and vaccination initiatives to further optimise strategies that combine convenient access to vaccinations with sustained incentives. Setting up HPV vaccination stations on campus could reduce the time it takes to get vaccinated. At the same time, creating dedicated health records for vaccinated students and providing personalised services, such as post-vaccination health monitoring, can address concerns about vaccination and help to advance vaccination efforts efficiently. Globally, HPV vaccination in men remains undervalued, despite evident that it can prevent penile cancer and other related diseases [66, 67], and contributes to herd immunity [68]. Therefore, more research is needed to understand the HPV vaccination status of male university students. In consideration of the relatively limited propensity among males to receive HPV vaccination at present, and the fact that the efficacy of high-cost interventions has not yet been fully validated through practical application. In order to balance the effectiveness of interventions with cost efficiency, it is recommended that cognitive guidance is prioritised as the core approach. Use the results from preliminary validation to inform subsequent economic investment decisions, and then optimise intervention strategies to avoid blind investments that lead to resource wastage. Furthermore, we also found that the vaccination intention rate of non-medical students (27.9%) was lower than that of medical students (60.5%). Previous research confirms that the advice from healthcare professionals has a significant impact on vaccination intention [69]. Interestingly, although medical students had a more positive attitude towards HPV vaccination, their actual vaccination rates were lower than those of non-medical students. Similar results were reported in a Hong Kong study, which attributed the discrepancy to concerns about vaccine cost and potential side effects [70]. Medical students, because of their professional knowledge, may assess the safety and efficacy of the vaccine in greater depth, resulting in overly cautious behaviour [71]. We recommend that countries develop communication strategies tailored to their cultural contexts in order to mitigate risk perception biases stemming from cultural differences, and to alleviate vaccine hesitancy driven by concerns about side effects [72]. Simultaneously, we should emphasise the responsibility of medical students, as future healthcare practitioners, to promote vaccines and enhance vaccination initiatives. In many regions of the world, the HPV vaccine does not form part of the public health budget [73, 74]. The cost of vaccination represents a significant financial burden for university students who are often financially dependent and may hesitate despite having sufficient nowledge and a positive attitude [75, 76]. Furthermore, the regional disparities in economic development further exacerbate the impact of costbarriers on HPV vaccination behaviour [77]. In some developed countries, measures such as regional government subsidies and health insurance reimbursement reduce the cost of vaccination, contributing to higher uptake [78, 79]. This is particularly evident in the number of students who have received all 3 doses of the vaccine. Among the 5 relevant studies, 3 were conducted in the United States, where stronger policy support likely played a role [80]. In contrast, students in economically underdeveloped regions of Asia and Africa [81, 82] are required to bear the entire cost of vaccination on their own [83]. As a result, the high cost deters many students, including medical students, from receiving the vaccine [84], which severely limits the increase in HPV vaccination rates. Though scientific evidence has been available to clarify misconceptions about the safety of the vaccine [85], concerns about potential side effects of the vaccine still exist among the university students [86]. While studies have confirmed the vaccine’s safety and effectiveness, a study by Deriemaeker et al.[87] among Belgian students also demonstrated the limited effect of simple generalisation of knowledge on increasing HPV vaccination rates, especially when perceived personal relevance is low. Following the global outbreak of the coronavirus disease 2019(COVID-19)in 2020, the economies of various countries were affected by the pandemicthe global pandemic [88]. This led not only to reduced attention being paid to HPV vaccines, resulting in vaccination rates falling short of ideal levels, but also compounded the long-standing issue of global HPV vaccine supply shortages, further exacerbating vaccination challenges. In fact, as early as 2018, the global supply of HPV vaccines faced constraints due to insufficient manufacturing capacity [89]. At that time, Gavi (the Vaccine Alliance) and its partners were notified by vaccine manufacturers of impending supply shortages. As national HPV vaccination programmes progressed, demand continued to grow, widening the supply gap. It has created a situation in which countries seeking to increase vaccination rates through policy changes are faced with the practical obstacle of “no vaccine available”, which is a key global factor hindering HPV vaccination uptake. This systematic review and meta-analysis provides a scientific basis for a comprehensive understanding of the university student population in terms of HPV and its vaccine-related aspects, and for the development of intervention strategies to increase vaccination rates. In lower-income region, improving vaccine supply and accessibility should be a priority. It is recommended that governments augment investment in HPV vaccination and provide subsidies or free immunisation services for university students [90]. Securing vaccine donations through collaboration with international organisations such as Gavi, the Vaccine Alliance can help reduce procurement and administration costs. For example, as the inaugural low-income nation to implement a nationwide HPV vaccination programme [91, 92], Rwanda’s vaccination planning successfully achieved high coverage through collaboration with educators and healthcare workers, effective social mobilization, and school-based targeting strategies [93, 94]. This model offers valuable lessons for other resource-constrained regions. In higher-income countries, efforts should focus not only on disseminating information but also on improving the health literacy and risk perception to promote the transition from intention to action [95]. Universities-based programs should target gender-sensitive health education covering HPV-related diseases, including cervical and vaginal cancers in females, penile cancer in men, and oropharyngeal, anal cancers, and condyloma acuminatum in both sexes [96]. Evidence suggests that vaccine delivery through university systems achieves higher coverage rates than through health facilities, suggesting that collaboration between the health sector and universities should be strengthened [97]. At the individual level, factors such as vaccine cost and privacy concerns may lead to[98] university students to underestimate their risk of HPV infection [99]. Targeted interventions, such as peer education, could address this gap [100–102] training students as peer educators allows for the dissemination of knowledge about HPV among their classmates and the communication through trusted and relatable channels, especially within medical faculties. Moreover, social media has become an increasingly important source of health information [103, 104]. In view of the expediency of online channels in the dissemination of health-related information, it is recommended that established online platforms such as official campus accounts be utilised to supplement content specialising in HPV vaccination services, thereby aiding students in the alleviation of their concerns. Strengths and limitations A major strength of this study is the substantial sample size, encompassing a total of 56 studies and 184,351 individuals. Additionally, a thorough quality assessment was conducted, evaluating aspects such as data completeness, study design, and sample representativeness. This rigorous and meticulous approach enhances the scientific validity and reliability of the findings. However, several limitations should be noted. First, all included studies were cross-sectional, limiting causal inference. Subsequent research should incorporate longitudinal designs to better understand temporal changes in vaccination intention and behavior. Second, most included studies were conducted in Asia, potentially limiting the generalizability for more diverse population. Future studies are recommended to focus more on other geographic scopes to improve comprehensiveness. Third, the diversity in knowledge assessment instruments and disparate assessment criteria across studies may limit the comparability of knowledge-related findings. In the future, the development and validation of standardised knowledge scales is recommended to improve future evaluations of HPV awareness among university students. Conclusion This systematic review and meta-analysis found that awareness of HPV and its vaccine was suboptimal among university students globally. Knowledge gaps were particularly evident regarding the asymptomatic nature of the infection and the optimal timing for vaccination. Only 52.9% of students were willing to be vaccinated against HPV, with higher willingness observed among female and medical students. However, the actual vaccination rate was significantly lower, at just 10.4%. Regional subgroup analyses showed higher vaccination rates in Europe and North America. Our findings highlight the need for targeted intervention strategies, such as collaboration between public health departments and universities, peer-led education to address misconceptions and boost HPV vaccination rates among university students. Supplementary Information Supplementary Material 1. Supplementary Material 1.